Leukeran2 mg

Leukeran is an alkylating chemotherapy agent (nitrogen mustard derivative) used in the treatment of certain lymphoproliferative malignancies. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Chronic lymphocytic leukemia (CLL): Leukeran is indicated for the treatment of CLL, including symptomatic disease requiring cytoreduction, typically in patients for whom it is deemed an appropriate choice.
• Malignant lymphomas: including lymphosarcoma, giant follicular lymphoma (follicular lymphoma), and Hodgkin lymphoma, particularly in patients where more aggressive combination regimens are not suitable.

Guideline-supported / adjunct and off-label uses

• Steroid-resistant or steroid-dependent nephrotic syndrome in children (typically minimal change disease), used off-label under pediatric nephrology supervision when corticosteroid therapy alone is inadequate.
• Waldenström macroglobulinemia and selected other low-grade lymphoproliferative disorders, used off-label, sometimes as part of combination regimens.
• Autoimmune conditions (e.g. selected severe autoimmune cytopenias, uveitis) as an off-label, specialist-directed, second/third-line immunosuppressive option when standard therapies fail.

Leukeran must only be prescribed and monitored by an oncologist, hematologist, or relevant specialist; it is not a general-practice or self-titrated medication.

Each film-coated tablet contains Chlorambucil USP as the active ingredient, along with pharmaceutical excipients required for tablet formulation (such as diluents, binders, and film-coating agents). Chlorambucil is chemically a bifunctional nitrogen mustard alkylating agent.

Leukeran is an orally administered, bifunctional alkylating agent belonging to the nitrogen mustard class of chemotherapy drugs. It has been used for decades in the management of chronic lymphocytic leukemia and certain lymphomas. It works by cross-linking DNA strands within malignant lymphocytes, preventing cell replication and ultimately causing cell death.

Leukeran carries an FDA boxed warning for carcinogenic potential (risk of secondary malignancies, including acute leukemia, particularly with prolonged treatment) and for mutagenic and reproductive toxicity (risk of infertility, particularly in males, and teratogenicity). Because of its narrow therapeutic index and significant toxicity profile, Leukeran must be prescribed, dosed, and monitored exclusively by an oncology or hematology specialist.

Leukeran belongs to the alkylating agent class of antineoplastic (cytotoxic chemotherapy) drugs, specifically the nitrogen mustard subclass.

Chlorambucil is a bifunctional alkylating agent. It forms covalent cross-links between the N7 position of guanine bases on opposing strands of DNA (interstrand cross-linking), and can also cause DNA-protein cross-links and single-strand breaks. This cross-linking prevents DNA strand separation, blocking DNA replication and RNA transcription.

Because its cytotoxic mechanism does not depend on active cell division, Chlorambucil affects both rapidly dividing malignant lymphocytes and, to some extent, resting cells, though proliferating cells are generally more sensitive. This ultimately triggers apoptosis of malignant lymphoid cells. Chlorambucil is well absorbed orally, extensively metabolized in the liver (including conversion to the active metabolite phenylacetic acid mustard), and eliminated primarily via hepatic metabolism with a plasma half-life of approximately 1.5 hours for the parent drug.

Leukeran is for oral use only. Tablets should be swallowed whole with water on an empty stomach, at a consistent time each day. Do not crush, split, or handle tablets with bare hands; caregivers should use gloves when handling this cytotoxic medication, and avoid contact with skin, eyes, or mucous membranes. Wash hands thoroughly after administration.

Only well-established, clinically significant interactions are listed below.

• Other myelosuppressive chemotherapy agents or radiation therapy: concurrent or recent use increases the risk of additive/cumulative bone marrow suppression; combination should only occur under specialist supervision with intensified blood count monitoring.
• Live vaccines: Leukeran-induced immunosuppression increases the risk of disseminated infection from live-attenuated vaccines; live vaccines should generally be avoided during and for a period after treatment.
• Phenytoin: there have been reports of reduced phenytoin absorption/efficacy during Leukeran therapy; seizure control and phenytoin levels should be monitored in patients on concurrent therapy.
• Other hepatotoxic drugs: concurrent use may increase the risk of liver injury, given Leukeran's hepatic metabolism; liver function should be monitored.

The most common and clinically significant adverse effects of Leukeran include:

• Myelosuppression (most common, dose-limiting): leukopenia, neutropenia, thrombocytopenia, and anemia; blood counts can continue to fall for some time even after the last dose, requiring ongoing monitoring after stopping treatment (see Precautions).
• Gastrointestinal: nausea, vomiting, and mouth ulceration, generally mild at standard doses.
• Hepatotoxicity: elevated liver enzymes, jaundice (uncommon but reported).
• Neurological: seizures, particularly with high doses (see Precautions).
• Dermatological: skin rash; rare severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
• Pulmonary: rare pulmonary fibrosis with long-term use.
• Reproductive: infertility, particularly in males, which can be irreversible (see Precautions).
• Secondary malignancy: increased long-term risk of secondary cancers, including acute leukemia (see Precautions/boxed warning).

Leukeran is contraindicated in pregnancy. It is a cytotoxic alkylating agent with confirmed teratogenic potential in humans and can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for a period after completing therapy, and pregnancy should be excluded before starting therapy. If pregnancy occurs or is suspected during treatment, the patient should be advised of the potential risk to the fetus and referred urgently to the treating specialist.

Leukeran is excreted into breast milk; because of the potential for serious adverse effects in a nursing infant, breastfeeding should be avoided during treatment with Leukeran and for an appropriate period after the last dose, as advised by the treating physician.

Leukeran carries an FDA boxed warning and requires close specialist supervision. Key precautions:

• Carcinogenic potential (boxed warning): secondary malignancies, including acute leukemia, have been reported with Leukeran use, particularly with prolonged treatment; long-term surveillance is advised.
• Mutagenic and reproductive toxicity (boxed warning): Leukeran can cause infertility, particularly in males, which may be irreversible, and is teratogenic; fertility preservation counseling should be discussed before starting therapy if relevant.
• Myelosuppression: the dose-limiting toxicity; regular complete blood counts are required during treatment, with counts sometimes continuing to fall for a period after the last dose, so monitoring must continue even after stopping.
• Seizures: have been reported, particularly at high doses; use with caution in patients with a seizure history.
• Hepatotoxicity: periodic liver function monitoring is recommended.
• Skin reactions: including rare severe reactions; treatment should be stopped and medical attention sought if a severe skin reaction develops.
• Specialist-only use: Leukeran requires administration and dose individualization by an oncology/hematology specialist and must never be self-titrated or continued/stopped without specialist advice.

Overdose of Leukeran is a medical emergency. Expected effects primarily reflect exaggerated bone marrow suppression (severe leukopenia, thrombocytopenia, and anemia, which may be delayed in onset), and potentially seizures or gastrointestinal symptoms. There is no specific antidote. Anyone who has taken more than the prescribed dose of Leukeran, or shows signs of overdose, should seek immediate medical attention or contact emergency services/poison control; management is supportive, with close hematologic monitoring in a hospital setting.

Store in a refrigerator at 2°C to 8°C, protected from light and moisture. Do not freeze. Keep out of reach and sight of children. Handle with gloves as a cytotoxic medication and dispose of unused tablets according to local pharmaceutical waste guidance rather than household waste.

Elderly

Elderly patients may be more susceptible to myelosuppression; dose selection should be cautious, typically starting at the lower end of the dosing range with close monitoring.

Renal impairment

No formal validated dose-adjustment guidelines exist; use with caution and enhanced monitoring.

Hepatic impairment

Use with caution given hepatic metabolism; dose reduction and closer monitoring of liver function and blood counts are recommended in significant hepatic impairment.

Pediatric population

Leukeran is not FDA-approved for pediatric leukemia/lymphoma indications; safety and efficacy for those indications have not been established in children. It is used off-label in children for steroid-resistant/dependent nephrotic syndrome under pediatric nephrology supervision only (see Pediatric Uses).

Duration of Leukeran therapy is individualized by the treating specialist based on indication, response, and tolerability. For CLL and lymphomas, courses commonly run several weeks with response assessed via blood counts and clinical status before continuation or adjustment. For off-label pediatric nephrotic syndrome, courses are typically limited (e.g. around 8-12 weeks) to reduce cumulative toxicity and infertility risk. Treatment should never be extended, shortened, or restarted without the treating specialist's explicit direction.

Chlorambucil: Antineoplastic agent, alkylating agent, nitrogen mustard class.

Chlorambucil alkylates DNA by forming interstrand cross-links (primarily at the N7 position of guanine), preventing DNA strand separation and thereby blocking DNA replication and RNA transcription, which triggers apoptosis in malignant lymphoid cells.

D

Leukeran is not FDA-approved for chronic lymphocytic leukemia or lymphoma in pediatric patients; safety and efficacy for these indications have not been established in children. It is used off-label, under pediatric nephrology supervision only, for steroid-resistant or steroid-dependent nephrotic syndrome (typically minimal change disease) in children, at carefully individualized, weight-based doses for a limited treatment course. Because of the risk of infertility and secondary malignancy, use in children requires careful specialist risk-benefit assessment and is never appropriate for self-directed or non-specialist use.